

Wholesale Acquisition Cost Information for Colorado Prescribers

MYFEMBREE® (relugolix, estradiol, and norethindrone acetate)

Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products listed below.

NDC	Myovant Sciences, Inc. Product	Dosage Form	Strength	Unit Size	WAC*
72974-415-01	MYFEMBREE®	Tablet	relugolix 40 mg / estradiol 1 mg / norethindrone acetate 0.5 mg	28	\$1,034.96

The price paid by patients to acquire the products listed is often different than the WAC prices listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy.

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” The following generic prescription drugs are in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed Myovant Sciences products: There are no generic prescription drugs for MYFEMBREE.

*Pricing as of December 30, 2021. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reduction in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.

MYFEMBREE® is a trademark of Myovant Sciences GmbH.